AstraZeneca completes exclusive license deal for ZEGFROVY
AstraZeneca (AZN) announced the successful completion of its previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY (sunvozertinib), an oral irreversible EGFR inhibitor for lung cancer patients.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.